Sana Biotechnology Inc (SANA) USD0.0001

Sell:$1.88Buy:$1.89$0.01 (0.53%)

NASDAQ:1.51%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.88
Buy:$1.89
Change:$0.01 (0.53%)
Market closed | Prices delayed by at least 15 minutes
Sell:$1.88
Buy:$1.89
Change:$0.01 (0.53%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.

Key people

Steven D. Harr
President, Chief Executive Officer, Principal Financial Officer, Director
Richard Mulligan
Vice Chairman of the Board
Tricia Stewart
Chief People Officer, Executive Vice President
Dhavalkumar Patel
Executive Vice President, Chief Scientific Officer
Bernard J. Cassidy
Executive Vice President, General Counsel, Company Secretary
Christian Hordo
Executive Vice President, Chief Business Officer
Hans Edgar Bishop
Independent Chairman of the Board
Joshua H. Bilenker
Independent Director
Douglas G. Cole
Independent Director
Robert Nelsen
Independent Director
Alise S. Reicin
Independent Director
Click to see more

Key facts

  • EPIC
    SANA
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US7995661045
  • Market cap
    $428.41m
  • Employees
    194
  • Shares in issue
    225.48m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.